Endur Asa (0JGO)
LSE
BerGenBio to Present Late-breaking Abstract on Phase II Trial of Bemcentinib in Combination With KEYTRUDA® in Advanced NSCLC at SITC PR Newswire BERGEN, Norway, Nov. 2, 2018 - Combination of...
BerGenBio to Present Late-breaking Abstract on Phase II Trial of Bemcentinib in Combination With KEYTRUDA® in Advanced NSCLC at SITC - Combination of selective AXL inhibitor bemcentinib and...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 1.628 | 1.628 | 1.628 | 143 | 1.628 | DE |
4 | 0 | 0 | 1.628 | 1.628 | 1.628 | 1197 | 1.628 | DE |
12 | 0 | 0 | 1.628 | 1.628 | 1.628 | 1429 | 1.628 | DE |
26 | 0 | 0 | 1.628 | 1.628 | 1.628 | 848 | 1.628 | DE |
52 | 0 | 0 | 1.628 | 1.628 | 1.628 | 431 | 1.628 | DE |
156 | 0 | 0 | 1.628 | 1.628 | 1.628 | 161 | 1.628 | DE |
260 | 0 | 0 | 1.628 | 1.628 | 1.628 | 161 | 1.628 | DE |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約